

9 February 2021

## Dabur India – BUY

**CMP** :Rs.529.0  
**Target Price** :Rs.633.0  
**Upside** : 20%+  
**Stop Loss** :Rs.462.0 (Closingbasis)

### Investment Thesis

Recently, the stock price of Dabur India Ltd. (Dabur) corrected by ~5% from 52-week high of Rs.552.55 despite reporting good set of numbers in the recent quarters as Dabur is one of the biggest beneficiary of increased healthawareness in a post-Covid world.

Dabur has emerged from a general FMCG company to a less traditional consumer-oriented healthcare company, focused to new-age consumers. It has developed a well-diversified product portfolio catering to different segments. Dabur is re-branding its product range, like Pudim Hara, Chyawanprash, Hajmola and Dashmularishta as more youth-oriented under its 'Getting the future ready' strategy. Presently, ~35% of its domestic revenue comes from health-positioned brands, which it plans to increase gradually over time. We believe, competition raised from Patanjali has subsided significantly, resulting in high double-digit growth of Dabur Red and Dabur Honey (that competes with Patanjali). We believe, Dabur will grow by double-digit growth, driven by high volume growth with focus on power brands and low unit price products in FY20-22E.

Dabur generates ~45% of its revenue from rural market as against ~35% for the industry. Domestic FMCG sales growth moderated due to rural slowdown post lockdown, liquidity crunch and prolonged winter, which impacted hair care and foods segments in FY20. The international business growth remained muted due to continued weakness in MENA region and adverse currency in Turkey, Nigeria and Pakistan. We believe steady focus on expanding direct reach in rural areas would augment the volume growth in future. Out of the total 6.6 lakh villages in India, 66,000 generate ~50% of rural FMCG sales. Dabur has a direct reach to 44,000 of these villages, which it plans to increase to 51,000 by FY21E.

### Financials

- During the past 5 years, revenue of Dabur grew at a CAGR of 2.1% while PAT grew at a CAGR of 6.3% in the same period.

Consol. (Rs.Mn)	FY18	FY19	FY20	FY21E	FY22E
Revenue	77,219	85,150	86,846	99,873	114,854
EBITDA	16,174	17,396	17,924	20,612	23,704
% growth	7.2	7.6	3.0	15.0	15.0
PAT	13,544	14,423	14,450	16,689	19,276
EPS (INR)	7.7	8.2	8.2	9.4	10.9
P/E (x)	68.6	64.6	64.5	55.9	48.4
RoE (%)	24.1%	26.0%	22.2%	23.4%	24.6%

- Dabur has reported 16.0% YoY growth in revenue in Q3FY21 to Rs.27,288mn driven by 18.1% YoY volume growth supported by strong traction in health supplement, oral care, OTC & ethical businesses.

### Stock Data

Market Cap (Rs. Mn)	9,31,610
Market Cap (\$ Mn)	12,761.8
Shares O/S (in Mn)	1,767.1
Avg. Volume (3 month)	2,652,000
52-Week Range (Rs.)	552.55/ 386.05

### Shareholding Pattern

Promoters	67.87%
FIIIs	18.52%
Institutions	5.93%
Others (incl. body corporate)	7.68%

Performance (%)	1M	6M	1Yr
Absolute	-1.6%	2.3%	8.2%
BSE FMCG	-2.0%	8.7%	9.3%

### Key Ratios

Div Yield	0.6%
TTM PE	58.4x
ROE	23.0%
TTM EPS (Rs.)	9.0/-

- Dabur's higher penetration led growth continued in health supplement and oral care segments with 34.7% and 28% jump in sales, respectively. New products (launched in the last three quarters) contributing 4-5% to the sales in Q3FY21.
- EBITDA of Dabur has increased by 16.5% YoY to Rs.5,742mn in Q3FY21. However, EBITDA margin has only improved by 9bps to 21.0% in Q3FY21 as the company has significantly (170 bps) increased its media spends largely investing behind core/power brands.

## Key Business Highlights

- Dabur is amongst the top FMCG companies in India, operate in key consumer products categories like Hair Care, Oral Care, Health Supplements, Digestives, OTC & Ethicals, Skin Care, Home Care and Foods. Dabur is also a leader in Ayurvedic products with a portfolio of over 250 Herbal/Ayurvedic products.
- Flagship brands of Dabur consist of Dabur Amla, Dabur Chyawanprash, Vatika, Réal, Dabur Red Toothpaste, Babool, Hajmola, Dabur Honey, Glucose, Fem and Odonil.
- It has a wide distribution network, covering over 5.3 million retail outlets with a high penetration in both urban and rural markets. Dabur's international business spread into the US, Egypt, Nigeria, Bangladesh and Nepal and contributes ~26% to revenues.

## Valuation

- Dabur is better placed compared to its peers given its presence in high-margin countries and categories. Of late, Dabur's international business, which contributes 26% to its consolidated revenue, has seen growth issues. Hyperinflation in Egypt, demand slowdown in GCC countries on account of fall in crude oil prices and adverse currency fluctuation has dented its performance in the Middle East and North Africa (MENA) region. However, due to the recent spike in crude oil prices, this highly profitable MENA region is expected to report a better performance. Dabur has been able to maintain 20-21% EBITDA margin, which will improve further once there is improvement in overseas business. It has taken a price hike of 1.5% during the quarter, which it expects to remain at ~2% for the year. It also expects to maintain operating margins at 20-21% going ahead.
- Dabur has a strong set of brands, of which, three brands generate more than Rs.10bn revenue each (Amla, Real and Vatika) and another 16 bring in at least Rs.1bn each. This hasn't stopped the efforts at innovation/re-innovation or re-positioning. Thus, Dabur is targeting several youth-centric products and categories such as milk shakes and drinking yoghurt, now being test marketed and will be soon rolled out nationally. In fact, in the recent past it has successfully rolled out several products/variants like Chyawanprash Sugar Free, Hajmola Anardana and Odomos roll-on and wear-on patches.
- With developed a well-diversified product portfolio, decline in competition from Patanjali, plans to increase rural reach, increase in margin due to benign cost inflation and plans to target youth-oriented brands, we value Dabur at 58.0x FY22E EPS of Rs.10.90 to arrive at target price of Rs.633.00, an upside of ~20%.

## Risk & Concern

- Rural India is largely dependent on monsoons and Dabur's ~50% of the domestic sales comes from rural India. Thus, below normal rainfall can affect the volumes growth of Dabur going ahead.
- Sudden rise in inflation caused by supply disruptions of crude oil could bring operating margins under pressure.
- Any increase in competitions from ayurvedic oriented company like Patanjali may pressure on growth of Dabur.

## Graphs & Charts

Figure 1: Net Sales Trend




Figure 2: EBITDA & EBITDA Margin Trend




Figure 3: PAT Trend





Figure 4: Ad-Spend to Net Sales Trend



Name  
Jitendra Upadhyay

Designation  
Research Analyst

**Disclosure:**

Bonanza Portfolio Ltd here by declares that views expressed in this report accurately reflect view point with subject to companies/securities. Bonanza Portfolio Ltd is responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations. Bonanza Portfolio Ltd or its associates or Analyst or his relatives may or may not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

Bonanza Portfolio Ltd operates under the regulation of SEBI RegnNo.INM000012306

**Disclaimer:**

This research report has been published by Bonanza portfolio Ltd and is meant solely for use by the recipient and is not for circulation. This document is for information purposes only and information / opinions / views are not meant to serve as a professional investment guide for the readers. Reasonable care has been taken to ensure that information given at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. If this report is inadvertently send or has reached to any individual, same may be ignored and brought to the attention of the sender. Preparation of this research report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Past performance is not a guide for future performance. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by Bonanza portfolio Ltd to be reliable. This report should not be taken as the only base for any market transaction; however this data is representation of one of the support document among other market risk criterion. The market participant can have an idea of risk involved to use this information as the only source for any market related activity. The distribution of this report in definite jurisdictions may be restricted by law, and persons in whose custody this report comes, should observe, any such restrictions. The revelation of interest statements integrated in this analysis are provided exclusively to improve & enhance the transparency and should not be treated as endorsement of the views expressed in the analysis. The price and value of the investments referred to in this report and the income from them may go down as well as up. Bonanza portfolio Ltd or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of Bonanza portfolio Ltd shall be liable. Research report may differ between Bonanza portfolio Ltd RAs and other companies on account of differences in, personal judgment and difference in time horizons for which recommendations are made. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. Research analyst have not received any compensation/benefits from the subject company or third party in connection with the research report

Bonanza Portfolio Ltd. Bonanza House, Plot No. M-2, Cama Industrial Estate. Walbhat Road, Goregaon (E), Mumbai – 400063

Web site: <https://www.bonanzaonline.com>

SEBI Regn. No.: INZ000212137

BSE CM: INB 011110237 | BSE F&O: INF 011110237 | MSEI: INE 260637836

| CDSL: a) 120 33500 | NSDL: a) IN 301477 | b) IN 301688 (Delhi) | PMS: INP 000000985 | AMFI: ARN -0186

